SVB Leerink Starts Roivant Sciences (ROIV) at Outperform

SVB Leerink analyst David Risinger initiates coverage on Roivant Sciences (NASDAQ: ROIV) with a Outperform rating and a price target of $6.00.

The analyst comments "We are initiating coverage of ROIV shares with an Outperform rating and a $6 PT. ROIV’s market cap is $2.6bn, tapinarof could be a $2B+ drug, and the company has a broad portfolio of pipeline and platform assets. We believe Roivant’s management team is building a company with substantial long-term value creation potential. We anticipate positive catalysts for blockbuster topical dermatology candidate tapinarof, including commercialization in psoriasis this summer and pivotal atopic dermatitis readouts in 1H23."

For an analyst ratings summary and ratings history on Roivant Sciences click here. For more ratings news on Roivant Sciences click here.

Shares of Roivant Sciences closed at $3.70 yesterday.

You May Also Be Interested In

• Berenberg Starts Interparfums SA (ITP:FP) at Buy
• Melius Starts GE Vernova (GEV) at Hold
• BofA Securities Reinstates Indraprastha Gas Ltd. (IGL:IN) at Buy